We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 1 december 2017

The Lancet: [Corrections] Corrections

[Corrections] Corrections
Begeman L, GeurtsvanKessel C, Finke S, et al. Comparative pathogenesis of rabies in bats and carnivores, and implications for spillover to humans. Lancet Infect Dis 2017; published online Oct 31. http://dx.doi.org/S1473-3099(17)30574-1. The affiliation for L Begeman, C GeurtsvanKessel, Prof M Koopmans, and Prof T Kuiken should have been "Department of Viroscience, Postgraduate School Molecular Medicine, Erasmus University Medical Centre, Rotterdam, Netherlands". This correction has been made to the online version as of Nov 29, 2017 and will be made to the printed Review.
Read more

[Articles] HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis
Pretreatment drug resistance is increasing at substantial rate in LMICs, especially in sub-Saharan Africa. In 2016, the prevalence of pretreatment NNRTI resistance was near WHO's 10% threshold for changing first-line ART in southern and eastern Africa and Latin America, underscoring the need for routine national HIV drug-resistance surveillance and review of national policies for first-line ART regimen composition.
Read more

[Comment] Time to overcome pretreatment HIV drug resistance
Antiretroviral therapy (ART) coverage among people living with HIV reached 53% worldwide in 2016, representing 21 million people on treatment.1 As the number of people accessing ART increases, the prevalence of pretreatment drug resistance has increased in several low-income and middle-income countries (LMICs).2 A recent WHO report showed that the prevalence of pretreatment resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) surpassed 10% in six of 11 countries surveyed.3 Is this a threat for the UNAIDS target of eliminating HIV as a concern for public health by 2030?
Read more

[Articles] Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
For tuberculosis case detection, sensitivity of Xpert Ultra was superior to that of Xpert in patients with paucibacillary disease and in patients with HIV. However, this increase in sensitivity came at the expense of a decrease in specificity.
Read more

[Comment] Performance of Xpert MTB/RIF Ultra: a matter of dead or alive
In our opinion, the implementation of the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) since 2010 has revolutionised molecular diagnosis of (multidrug-resistant) tuberculosis. Xpert combines early diagnosis of tuberculosis with direct detection of rifampicin resistance, but the limitations of the assay are its suboptimal sensitivity and high rate of false positivity in low-prevalence settings. To overcome these limitations, the assay was re-engineered to increase diagnostic sensitivity and improve specificity in the detection of rifampicin resistance.
Read more